Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO and the shorts continue | Pisd | investorshub | 10/03/2023 10:32:56 PM |
$OKYO What do you make of this? | Count Crypto | investorshub | 10/03/2023 10:26:12 PM |
$OKYO Good read | mfayman | investorshub | 10/03/2023 9:06:14 PM |
Lfg | Count Crypto | investorshub | 10/03/2023 8:42:32 PM |
Looks like we're OK-yo!... | Sirpeter | investorshub | 10/03/2023 8:30:46 PM |
$OKYO is it bear time? Or do we go bull? | Count Crypto | investorshub | 10/03/2023 5:05:10 PM |
Boom 2+$ solid day so far | mfayman | investorshub | 10/03/2023 4:27:14 PM |
$OKYO MomentumIts trading | mfayman | investorshub | 10/03/2023 3:48:27 PM |
$OKYO$$ breaking $2.. let's Goooo!!!!!!!!!! | Pisd | investorshub | 10/03/2023 3:44:57 PM |
$OKYO What do you make of this? | Count Crypto | investorshub | 10/03/2023 3:41:39 PM |
The trading | mfayman | investorshub | 10/03/2023 2:09:37 PM |
MomentumIts now | StocksNcash | investorshub | 10/03/2023 1:48:53 PM |
Price trading last trade up | mfayman | investorshub | 10/03/2023 12:50:22 PM |
$OKYO Looks pretty positive | mfayman | investorshub | 10/03/2023 12:25:07 PM |
$OKYO MomentumIts now | mfayman | investorshub | 10/03/2023 10:39:11 AM |
what does this mean? | mfayman | investorshub | 10/03/2023 10:17:34 AM |
$OKYO Long and strong lets hope im right | mfayman | investorshub | 10/03/2023 8:18:12 AM |
Do we have a winner?Turn around time? | mfayman | investorshub | 10/03/2023 7:00:53 AM |
$OKYO we got news | Sirpeter | investorshub | 10/03/2023 6:01:46 AM |
$OKYO The trading up | StocksNcash | investorshub | 10/03/2023 5:02:17 AM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...